Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
MONTREAL, Feb. 17, 2016 -- Ropack Pharma Solutions (RPS), provider of high-quality drug development, manufacturing and packaging of solid oral dosage, has hired Francois Chouinard, Ph.D., as Director of Business Development for R&D and Formulation. Chouinard will report to Paul Dupont, VP, Marketing and Business Development.
|
|||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/19f7d496-d231-4eab-b156-2d28fa040660
Chouinard, who holds a doctorate in Pharmaceutical Sciences, will focus on business development for the drug development facilities in Long Island, New York, purchased by RPS and most recently operated by Forest Labs. “Francois brings a deep understanding of the drug development process,” said Dupont. “His many years of success and experience working in the CDMO/CMO environment, along with his superior customer engagement skills and scientific background, are unique and valuable assets which will advance and support our mission to provide a superior customer engagement experience.”
An internationally experienced Pharma R&D leader, he brings more than 20 years of experience in the generic, contract development and biotech industries, developing more than 30 solid dose products for the Canadian and European markets. Prior to joining RPS, he was Executive Director of Product Development at Halo Pharmaceutical’s Montreal location where he was actively involved in the development of new business opportunities as well as the management of all product development.
“With Ropack Pharma Solutions now providing a complete range of contract development services, my product development experience in brand and generic Pharma will help RPS support the best development strategy for our customers and establish a high level of confidence in our ability to meet their timelines and product quality attributes,” noted Chouinard.
About Ropack Pharma Solutions
Ropack Pharma Solutions (RPS) supports solid oral dosage projects from early-stage formulation through clinical manufacturing, packaging, distribution and commercial manufacturing and packaging. Facilities in Montreal, Canada, and Long Island, New York, are cGMP-compliant, site-licensed by the FDA and Health Canada-certified.
Contact Paul Dupont Ropack Pharma Solutions 10801 Mirabeau, Montréal, Québec H1J 1T7, CANADA 514-353-7000 [email protected]
